ONCS hired former AVXS CEO Daniel OConnor. How responsible was he for AVXS technological innovation? I don't know. ONCS technology involves localized injection of a cytokine into tumor followed by the delivery of electrical pules Preliminary data in the combo therapy with Keytruda will be presented in 2018. Breakthrough Therapy & Fast Track Designations are possibilities. 2/28/18, Cash = $37.6mn giving them a runway into Q4/2018.